Loading patent…
AssigneeIsis Pharmaceuticals, Inc.
InventorsThazha P. Prakash, Brenda F. Baker, Anne B. Eldrup, Muthiah Manoharan, Balkrishen Bhat, Richard Griffey, Eric E. Swayze, Stanley T. Crooke
Estimating the term…
Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification. In some embodiments the modification is a 2′-F substituent group on a sugar moiety. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleoside of the oligomer has a modified sugar and/or backbone modification.
A composition comprising a first oligomer and a second oligomer, wherein:
A composition comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein, said protein comprising at least a portion of a RNA-induced silencing complex (RISC), wherein said oligomer includes includes at least one nucleoside having a 2′-F substituent group.
52 The composition of claim 51 wherein each of said nucleosides of said first type includes a 2′-F substituent group.
An oligomer having at least a first region and a second region, wherein:
Dependencies are inferred from the claim text.